These pathways also play a role in VEGF-induced angiogenesis, and its receptor VEGFR2 is also one of the targets of sulfatinib; hence, the anti-tumor effect could be enhanced by inhibiting angiogenesis (52). The gene discussed is VEGFA; the disease is neoplasm.